Abstract
Cholinesterases (ChEs) show increased activities in patients with Alzheimer’s disease, and remain one of the main therapeutic targets for treatment of this neurodegenerative disorder. A library of organoruthenium(II) complexes was prepared to investigate the influence of their structural elements on inhibition of ChEs, and on another pharmacologically important group of enzymes, glutathione S-transferases (GSTs). Two groups of organoruthenium(II) compounds were considered: (i) organoruthenium(II) complexes with p-cymene as an arene ligand, and (ii) organoruthenium(II) carbonyl complexes as CO-releasing molecules. Eight organoruthenium complexes were screened for inhibitory activities against ChEs and GSTs of human and animal origins. Some compounds inhibited all of these enzymes at low micromolar concentrations, while others selectively inhibited either ChEs or GSTs. This study demonstrates the importance of the different structural elements of organoruthenium complexes for their inhibitory activities against ChEs and GSTs, and also proposes some interesting compounds for further preclinical testing as ChE or GST inhibitory drugs.
Highlights
For at least 3500 years, precious metals have been used for different medicinal purposes, and it is known that the medicinal properties of metals are linked to their specific biological effects
We have focused on the study of the inhibitory activities of different organoruthenium(II) compounds against various enzymes, including ChEs (i.e., acetylcholinesterases (AChEs) and butyrylcholinesterases
We focused on anti-ChE and anti-glutathione S-transferases (GSTs) activities of two groups of ruthenium(II) compounds: organoruthenium(II) complexes with p-cymene as an arene ligand (Figure 1A), and organoruthenium(II) carbonyl complexes as CO-releasing molecules (CORMs) (Figure 1B)
Summary
For at least 3500 years, precious metals have been used for different medicinal purposes, and it is known that the medicinal properties of metals are linked to their specific biological effects. Ruthenium compounds show a broad spectrum of biological activities, which range from immunosuppressant, antibacterial, antiviral and antitumour, to antiparasitic effects. These activities are due to selective inhibition of many medicinally essential enzymes that are involved in different pathological conditions. These enzymes comprise in particular the cholinesterases (ChEs), glutathione S-transferases (GSTs), protein kinases, aldo-keto reductase, thioredoxin reductase, cathepsin B, topoisomerase II and HIV−1 reverse transcriptase, along with many others [5,6,7,8,9,10,11]. We have focused on the study of the inhibitory activities of different organoruthenium(II) compounds against various enzymes, including ChEs (i.e., acetylcholinesterases (AChEs) and butyrylcholinesterases
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
